|dc.creator||Ong M.-L.;Rajadhyaksha V.;Co V.M.;Talwar D.;PO-REN HSUEH;Mootsikapun P.||-|
|dc.description.abstract||Background: Candidemia is a significant cause of morbidity and mortality in hospitalized patients, particularly in Asia. Anidulafungin has been reported to be an effective treatment for candidemia in Western populations, but little is known about its efficacy in Asian patients, where the clinical presentation and epidemiology may be different.Methods: An open-label study of anidulafungin for the treatment of candidemia was recently conducted in several Asian countries. Treatment was initiated with intravenous anidulafungin, given for at least 5 days, with the option to complete treatment with oral voriconazole. The primary endpoint was global (clinical and microbiological) response, and the primary analysis was the proportion of patients in the modified intent-to-treat population with successful global response at the end of therapy. Secondary analyses included proportion with successful global response in clinically relevant patient subgroups. The safety and tolerability profile of anidulafungin and voriconazole in this population was also investigated.Results: Forty-three patients were studied, including 42 in the modified intent-to-treat population. Eighteen patients were > 65 years, the largest age subgroup, and 21 had central venous catheters. The most common Candida species causing infection were C. tropicalis (n = 18) and C. albicans (n = 10). In the primary analysis, 73.8% had a successful global response at end of therapy. Success rates in subgroups were: 72.2% for C. tropicalis and 71.4% for C. albicans infection, 58.8% for patients > 65 years, and 81.0% for patients with central venous catheters. Safety and tolerability were comparable with the known profiles for anidulafungin (and voriconazole).Conclusions: Although the epidemiology of Candida infections was different in this open-label study, the efficacy of anidulafungin in Asian patients with documented candidemia was consistent with previous studies in Western populations. No new safety concerns were identified.Trial registration: http://www.clinicaltrials.gov identifier NCT00537329. ? 2013 Mootsikapun et al.; licensee BioMed Central Ltd.||-|
|dc.relation.ispartof||BMC Infectious Diseases||-|
|dc.subject.other||anidulafungin; voriconazole; adult; aged; article; Asian; Candida albicans; Candida parapsilosis; Candida tropicalis; candidemia; candidiasis; clinical article; confusion; diarrhea; drug efficacy; drug eruption; drug hypersensitivity; drug response; drug safety; drug tolerability; drug withdrawal; female; human; hypokalemia; insomnia; loading drug dose; male; multicenter study; nonhuman; open study; phase 3 clinical trial; side effect; thirst; thorax pain; treatment duration; treatment outcome; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents; Candidemia; Echinocandins; Female; Humans; Male; Middle Aged; Pyrimidines; Treatment Outcome; Triazoles; Young Adult||-|
|dc.title||Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: Results from an open-label Phase III trial||en_US|
|Appears in Collections:||醫學院附設醫院 (臺大醫院)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.